Elana Thieme and Mark Mendoza, fourth-year graduate students in the Molecular and Cell Biology (MCB) PhD Program jointly ...

Scientists at Texas A&M University have discovered a way to recharge aging cells using flowers so small they make human hair ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...

GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...

Mission Bio, Inc., a leader in single-cell multi-omic solutions for precision medicine, announced that its Tapestri Platform and custom assay development supported initial exploratory biomarker ...

New Investigator Sponsored Data Suggest Trilaciclib May Mitigate Chemotherapy-Induced TP53-Mutant Clonal Hematopoiesis. EINPresswire/ -- Pharmacosmos Therapeutics Inc. today announced the presentation ...

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Use of MRI-guided focused ultrasound with standard chemotherapy is safe and may improve outcomes for people with glioblastoma ...

Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...